Skip to main content

Patients with Advanced/Metastatic NSCLC, Ovarian, Endometrial Cancers Recruited for Clinical Trial of First Antibody-Drug Conjugate Targeting PTK7

A phase 1 clinical trial now recruiting at Roswell Park Comprehensive Cancer Center is evaluating HWK-007, the first antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7). Associated with aggressive tumor growth, metastasis and treatment resistance, PTK7 is present in up to 70% of tumors and over-expressed in several cancer types.

Bailey Gleason Fitzgerald, MD, Assistant Professor of Oncology, Department of Medicine, is Site Principal Investigator of the study (NCT07444814), which is enrolling patients with non-squamous endothelial growth factor receptor wild type (EGFR Wt) non-small cell lung cancer (NSCLC), platinum-resistant ovarian cancer and endometrial cancer expressing PTK7. “First-generation antibody-drug conjugates have several important limitations, including unpredictable target expression-efficacy correlations that may reduce the number of patients who can benefit from these drugs, as well as inefficient linkers, which expose normal cells to unintended toxicity,” says Dr. Fitzgerald. “By leveraging a novel linker platform in combination with a broadly expressed target, it’s hoped that this new drug will overcome those limitations.”

The open-label trial comprises phase 1a, dose escalation, and phase 1b, dose expansion. Phase 1a will enroll patients with all three cancer types, while the backfill and expansion phases will enrich for the EGFR Wt NSCLC population. In this early-phase trial, investigators will focus primarily on safety and determining the maximum tolerated dose, maximum administered dose and recommended dose for expansion.

Roswell Park is the only site in New York State and one of only 12 in the nation to offer the trial, which is sponsored by Whitehawk Therapeutics Inc.



Powered by BroadcastMedBROADCASTMED
BroadcastMed Privacy Policy